AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01707225
Drug: Octreotide LAR Depot
RxNorm normalized name: octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subject will be seen in clinic every 4 weeks (+/- 4 days) through week 24. During weeks 25-36 the subject will receive a telephone call every 4 weeks +/- 4 days, from the research nurse to assess for changes occurring after the study drug was stopped. Subjects will receive a physical exam and interview at each visit to assess for any sign of GI bleeding at home as per standard protocol for HeartMate II patients and for potential drug related side effects. Labs collected for research will include monthly basic metabolic panel (BMP), complete blood count (CBC), fructosamine and quarterly HGbA1C , VEGF, vWF, vWF activity assay, thyroid stimulating hormone (TSH), platelet function test and fibrinogen. Subjects will receive their monthly injection while in clinic for their every 4 weeks appointment. The subjects will be followed and data will be collected for 36 weeks, or for as long as they are enrolled in the study.
Trial: NCT00003195
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00122694
Drug: carbon monoxide
RxNorm normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00108654
Drug: VRC-HIVADV014-00-VP
RxNorm normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03746275
Drug: Rivaroxaban (BAY59-7939, Xarelto)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2.5 mg twice daily
Trial: NCT03422354
Drug: Paravertebral block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive single shot L1-L2 PVB before undergoing GA
Trial: NCT00945308
Drug: Eptifibatide
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of Eptifibatide injected in two consecutive bolus of 180 mcg/kg each, followed immediately by continuous infusion of 2 mcg/kg/min for 12 hs.
Trial: NCT00945308
Drug: Eptifibatide
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection of Eptifibatide in two consecutive boluses of 180 mcg/kg followed by continuous intravenous injection dosing 2 mcg/kg/min for 12 hours
Trial: NCT00935194
Drug: oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg,bid,for 5 days
Trial: NCT00935194
Drug: oseltamivir and chinese medicinal herbs
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oseltamivir:75mg,p.o,bid,for 5 days; chinese medicinal herbs:200ml,p.o,qid,for 5 days
Trial: NCT00121277
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03030183
Drug: Zilucoplan (RA101495)
RxNorm normalized name: Zilucoplan
DrugBank: Zilucoplan (DB15636)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
Trial: NCT01729663
Drug: interferon alpha 2b
RxNorm normalized name: PEGINTERFERON ALPHA 2B 80MCG/0.5ML INJ,KIT
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03788616
Drug: Fuji IX EXTRA
RxNorm normalized name: factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-viscosity glass ionomer (Fuji IX EXTRA)
Trial: NCT03788616
Drug: ACTIVA KIDS bioactive restorative material
RxNorm normalized name: Mederma for Kids
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Modified composite (ACTIVA KIDS)
Trial: NCT03510910
Drug: Percocet
RxNorm normalized name: Percocet
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/acetaminophen (Percocet) 5 mg/325 mg as needed for breakthrough pain for patients in Percocet+ Acetaminophen group.~Percocet Group will receive standard of care Percocet 5 mg/325 mg every 6 hours PRN
Trial: NCT00141310
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04260347
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT00305487
Drug: Ciclesonide nasal spray
RxNorm normalized name: Ciclesonide Nasal Spray
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04034238
Drug: LMB-100
RxNorm normalized name: LMB-100
DrugBank: LMB-100 (DB18591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arms 1 and 2: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.
Trial: NCT01679353
Drug: caudal block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.5mL added to ropivacaine 0.15% 1.0 ml/kg was administered to Group R , Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.
Trial: NCT04034238
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arms 1 and 2: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.
Trial: NCT04295538
Drug: Elezanumab
RxNorm normalized name: Elezanumab
DrugBank: Elezanumab (DB15240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion; Intravenous (IV)
Trial: NCT00982254
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral insulin capsule formulation (150 U insulin/200 mg 4-CNAB in one capsule); single dose administration of 300 U insulin (in two capsules) and of 150 U insulin (one capsule) on two separate dosing days.
Trial: NCT02953275
Drug: vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: standard of care
Trial: NCT02953275
Drug: Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: added to vedolizumab
Trial: NCT01318525
Drug: ALF-5755
RxNorm normalized name: ALF component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg (25 ml) given in slow intravenous infusion over 10 minutes with an automatic syringe
Trial: NCT01318525
Drug: Saline solution (0.9% NaCl)
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 ml given in slow intravenous infusion over 10 minutes with an automatic syringe
Trial: NCT03936062
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin dispensing claim is used as the exposure
Trial: NCT00575978
Drug: Hydralazine
RxNorm normalized name: Hydralazine
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
Trial: NCT00069862
Drug: Deferitrin (GT56-252)
RxNorm normalized name: Deferitrin
DrugBank: Deferitrin (DB16132)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02272699
Drug: Nimotuzumab
RxNorm normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab 200mg per week for 6 weeks.
Trial: NCT02272699
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175mg per square metre on day 1, repeated every 3 weeks for 2 cycles.
Trial: NCT02272699
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 30mg per square metre on day 1 and day 2, repeated every 3 weeks for 2 cycles.
Trial: NCT01304706
Drug: Fluocinolone Acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2 μg/day
Trial: NCT00388557
Drug: vinflunine + ketaconazole
RxNorm normalized name: Ketoconazole
DrugBank: Vinflunine (DB11641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vinflunine solution for injection, ketaconazole tablets, vinflunine IV, ketaconazole oral, vinflunine 80 to 320mg/m2 + ketaconazole 400 mg, vinflunine every 3 wks, ketaconazole C1 only, variable duration
Trial: NCT04147650
Drug: 0.05% Voclosporin Ophthalmic Solution (VOS)
DrugBank: Voclosporin (DB11693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
Trial: NCT03263572
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intrathecally via spinal tap
Trial: NCT03263572
Drug: Ponatinib
RxNorm normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02466009
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 120 mg (3 tablets) each day for 21 days of a 28 day cycle with the possibility of an increase in the dose to 160 mg (4 tablets).
Trial: NCT04147650
Drug: Vehicle Ophthalmic Solution
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks
Trial: NCT02019589
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03493841
Drug: Alpha Lipoic Acid
RxNorm normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoic acid is an over the counter supplement. Two different forms, R and racemic are available. R-lipoic acid is the naturally occurring form. Racemic lipoic acid is the most commonly available supplement.
Trial: NCT02998827
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02998827
Drug: infliximab, azathioprine
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: other treatment include infliximab, azathioprine
Trial: NCT02655692
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA approved anesthetic medication with rapid acting antidepressant effects.
Trial: NCT02721511
Drug: Furosemide Injection Solution 8mg/mL
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide Injection Solution, 8 mg/mL, (total dose =80 mg) administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours by means of the B. Braun Perfusor® Space Infusion Pump System.
Trial: NCT00703482
Drug: Fenofibrate/CoQ10
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate pbo/CoQ10 placebo
Trial: NCT02376075
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intake of tablets containing 5 mg Linagliptin, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
Trial: NCT00703482
Drug: Fenofibrate/CoQ10
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate pbo/CoQ10 200 mg
Trial: NCT00703482
Drug: Fenofibrate/CoQ10
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate 160mg/CoQ10 placebo
Trial: NCT00703482
Drug: Fenofibrate/CoQ10
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate 80/CoQ10 100 mg
Trial: NCT00703482
Drug: Fenofibrate/CoQ10
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate 160mg/CoQ10 100 mg
Trial: NCT00703482
Drug: Fenofibrate/CoQ10
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate 80 /CoQ10 200 mg
Trial: NCT00703482
Drug: Fenofibrate/CoQ10
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate 160mg/CoQ10 200 mg
Trial: NCT02176161
Drug: Metformin Hydrochloride Extended Release 750mg
RxNorm normalized name: metformin hydrochloride Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.
Trial: NCT00110591
Drug: PRO 140
RxNorm normalized name: Climara Pro
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Monoclonal antibody to CCR5
Trial: NCT03097211
Drug: Nebicapone
RxNorm normalized name: Nebicapone
DrugBank: Nebicapone (DB14849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebicapone 150 mg tablets. Orally, with 240 mL of potable water.
Trial: NCT02728245
Drug: Dienogest
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dienogest 2mg po qd
Trial: NCT01388790
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously followed by once weekly subsequent intravenous infusion of cetuximab 250 mg/m\^2 in each 5-week treatment cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
Trial: NCT04059874
Drug: donafenib tablets
RxNorm normalized name: sorafenib Oral Tablet
DrugBank: CM-4307 (DB15414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: donafenib tablets 100mg qd dose group and donafenib tablets 100mg bid dose group
Trial: NCT01388790
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 60 mg/m\^2 will administered as intravenous infusion on Day 8 of each 5-week cycle maximum up to 8 cycles until disease progression, unacceptable toxicity, or withdrawal of consent
Trial: NCT01388790
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1, a combination of tegafur, gimeracil, and oteracil will be administered intravenously at a dose of 40 to 60 mg/m\^2 orally twice daily for first three consecutive weeks of 5-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
Trial: NCT03882489
Drug: Isobaric 2-chloroprocaine
RxNorm normalized name: 2-chloroprocaine
DrugBank: Procaine (DB00721)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The doses of isobaric 2-chloroprocaine will be administrated intrathecally and will be adjusted according to the observed responses in the previous subjects.
Trial: NCT03399474
Drug: Lidocaine Hydrochloride 2%
RxNorm normalized name: Lidocaine Hydrochloride 2% Topical gel
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine Hydrochloride 2%
Trial: NCT03399474
Drug: Dexmedetomidine 0.5 ug/kg
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pecedex
Trial: NCT03399474
Drug: Dexmedetomidine Injection 0.25 ug/kg
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pecedex
Trial: NCT02153788
Drug: Temazepam
RxNorm normalized name: Temazepam
DrugBank: Temazepam (DB00231)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Temazepam 15 mg orally at bedtime
Trial: NCT00269854
Drug: Infliximab 5 mg/kg
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
Trial: NCT00269854
Drug: Infliximab 10 mg/kg
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
Trial: NCT00269854
Drug: Infliximab 20 mg/kg
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 20 mg/kg will be administered as infusion at Week 0, 2 and 6.
Trial: NCT03575962
Drug: GSK3640254 Mesylate Salt Capsule
RxNorm normalized name: Ergoloid Mesylates Capsules
DrugBank: Ergoloid mesylate (DB01049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally (as single dose) on morning of Day 1, as 2 capsules of , 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
Trial: NCT01324323
Drug: Romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.
Trial: NCT01324323
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg oral once daily on Days 4-8
Trial: NCT00059917
Drug: polyglutamate camptothecin
RxNorm normalized name: pyroglutamate
DrugBank: Camptothecin (DB04690)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03132454
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03132454
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT03132454
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03132454
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00049517
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01298271
Drug: propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
Trial: NCT00049517
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given as a continuous infusion
Trial: NCT00049517
Drug: gemtuzumab ozogamicin (GO)
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00049517
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously daily for 3 days at a dose of either 45 or 90 mg/m2.
Trial: NCT04487574
Drug: XC221
RxNorm normalized name: XC221
DrugBank: XC221 (DB16503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive XC221 100 mg 2 times a day during 14 days
Trial: NCT02354313
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment Phase: consisting in an induction phase (3 cycles of RCHOP, given every 21 days); consolidation phase: (high-dose cyclophosphamide (CTX), 2 cycles of high dose Ara-C, BEAM and ASCT).~Randomization and maintenance phase: Patients who have achieved complete or partial response will be randomized between maintenance with lenalidomide or observation.
Trial: NCT00913666
Drug: Interferon beta-1a (Avonex)
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mcg by intramuscular injection once a week
Trial: NCT00887679
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-20 mg/day oral of Escitalopram for 6-weeks. Escitalopram flexible dose (10-20 mg/day). A forced escalation schedule of escitalopram was used to titrate it to the maximum tolerated dose. Drug was discontinued at the end of the study.
Trial: NCT03311334
Drug: DSP-7888 Dosing Emulsion
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DSP-7888 Dosing Emulsion will be administered intradermally (ID) every 7 days until cycle 3, and then every 14 days for combination with Nivolumab arm or every 21 days for combination with Pembrolizumab arm.
Trial: NCT03311334
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab will be administered in the approved dose and schedule starting on Day 29 of the study.
Trial: NCT03311334
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered in the approved dose and schedule starting on Day 22 of the study.
Trial: NCT00424866
Drug: FGF-1
RxNorm normalized name: Fibroblast Growth Factor-1
DrugBank: Fibroblast growth factor-1 (DB05599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg~Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg